Aridis Pharmaceuticals
Late-stage clinical biopharmaceutical company developing human-derived monoclonal antibody therapeutics and inhaled small-molecule anti-infectives for severe respiratory infections. Uses proprietary discovery and production platforms to recover rare, potent human B‑cells, convert them into manufacturing substrates, and advance candidates through preclinical studies and Phase 1–3 clinical trials with regulatory interactions including orphan and fast-track designations.
Industries
Nr. of Employees
small (1-50)
Aridis Pharmaceuticals
Patents
Products
AR-301
Fully human IgG1 monoclonal antibody targeting Staphylococcus aureus alpha‑toxin intended as adjunctive therapy for ventilator‑associated and hospital‑acquired pneumonia.
AR-501 (inhaled gallium citrate)
Inhalable gallium citrate small‑molecule anti‑infective formulated for pulmonary delivery to starve bacteria of iron and inhibit iron‑dependent metabolic pathways.
AR-101
Fully human monoclonal antibody against Pseudomonas aeruginosa LPS serotype O11 intended as adjunctive therapy to improve immune recognition and clearance.
AR-105
Broadly active fully human IgG1 monoclonal antibody targeting Pseudomonas aeruginosa alginate to neutralize biofilm/adhesion functions.
AR-320
Half‑life‑extended fully human IgG1 monoclonal antibody targeting S. aureus alpha‑toxin intended for preemptive treatment in colonized, mechanically ventilated ICU patients.
AR-701
Panel of fully human IgG1 monoclonal antibodies directed at conserved regions of SARS‑CoV‑2 spike/envelope proteins designed for broad coverage against variants.
AR-301
Fully human IgG1 monoclonal antibody targeting Staphylococcus aureus alpha‑toxin intended as adjunctive therapy for ventilator‑associated and hospital‑acquired pneumonia.
AR-501 (inhaled gallium citrate)
Inhalable gallium citrate small‑molecule anti‑infective formulated for pulmonary delivery to starve bacteria of iron and inhibit iron‑dependent metabolic pathways.
AR-101
Fully human monoclonal antibody against Pseudomonas aeruginosa LPS serotype O11 intended as adjunctive therapy to improve immune recognition and clearance.
AR-105
Broadly active fully human IgG1 monoclonal antibody targeting Pseudomonas aeruginosa alginate to neutralize biofilm/adhesion functions.
AR-320
Half‑life‑extended fully human IgG1 monoclonal antibody targeting S. aureus alpha‑toxin intended for preemptive treatment in colonized, mechanically ventilated ICU patients.
AR-701
Panel of fully human IgG1 monoclonal antibodies directed at conserved regions of SARS‑CoV‑2 spike/envelope proteins designed for broad coverage against variants.
Expertise Areas
- Monoclonal antibody discovery from human B‑cells
- Antibacterial and antiviral therapeutic development
- Inhaled anti‑infective formulation and pulmonary delivery
- Clinical trial management (Phase I–III) for respiratory infections
Key Technologies
- Single‑cell nanowell microarray screening
- CRISPR gene editing for cell line engineering
- CRISPR-based gene activation (CRISPRa) of endogenous regulators
- B‑cell fusion/immortalization for antibody production
News & Updates
Participation in healthcare and vaccine conferences and industry summits (2017–2018 event listings).
Top-line Phase 2a data reported for inhaled gallium citrate candidate indicating tolerability and high lung uptake in cystic fibrosis patients.
Reported Phase 2a safety/efficacy trends for a human anti‑S. aureus antibody and ongoing/completed Phase 2/3 studies for other mAb candidates.
Participation in healthcare and vaccine conferences and industry summits (2017–2018 event listings).
Top-line Phase 2a data reported for inhaled gallium citrate candidate indicating tolerability and high lung uptake in cystic fibrosis patients.
Reported Phase 2a safety/efficacy trends for a human anti‑S. aureus antibody and ongoing/completed Phase 2/3 studies for other mAb candidates.